AVITA Medical Hits Key Milestones as Third Quarter Revenue Surges 53%
AVITA Medical, Inc., a global leader in regenerative medicine technologies, made significant strides in the third quarter of this year, with revenue reaching $26.1 million – a 53% increase from the same period last year and 20% higher than the second quarter.
The company's growth can be attributed to the increasing adoption of its RECELL product, which is designed for treating serious burn injuries. Cohealyx, another key offering, also contributed to the revenue surge. As a result, AVITA Medical is raising its full-year revenue guidance for the second consecutive quarter.
According to Kerry, Vice President of Investor Relations, the company's progress builds on previous quarters' achievements. The team's efforts to stabilize RECELL utilization, rebuild engagement with core accounts, and improve operational efficiency have paid off. In the first quarter, these actions began to yield more consistent demand, which further accelerated in the second quarter.
Q3 saw significant growth within existing accounts, with hospitals ordering more RECELL units and Cohealyx reaching additional customers. The revenue increase has led to lower cash usage, solidifying AVITA Medical's position as a financially stable company. David O'Toole, Chief Financial Officer, will elaborate on the financial results and liquidity in more detail during the conference call.
RECELL, which played a crucial role in treating patients affected by the devastating fire at the Wainwright Military Base in Alberta, Canada, has demonstrated remarkable potential. The company mobilized quickly to donate several RECELL units to burn centers in Calgary and Edmonton, sending staff to train and support clinical teams. This swift response highlights AVITA Medical's commitment to helping people heal from serious wounds.
David O'Toole will discuss the financial results, but one thing is clear: AVITA Medical's growth trajectory remains strong. The company has achieved a significant milestone by reaching $26.1 million in revenue and has set its sights on even greater achievements.
A key highlight of Q3 was the impressive performance of RECELL, with U.S. revenue reaching $22.4 million – a 20% increase over the previous quarter. The number of units sold also saw significant growth, increasing to 3,196 units in the third quarter, up approximately 21% sequentially.
As AVITA Medical continues on its path forward, it is evident that the company's focus on commercial approach and targeted market has paid off. By targeting high-volume burn and Level I trauma centers, where clinicians treat burns, traumatic injuries, and complex surgical wounds, the company has established a strong foundation for future growth.
The estimated U.S. addressable market for AVITA Medical stands at approximately $1.3 billion annually, providing ample opportunities for expansion within its core market. As the company looks to the future, it is clear that Q3 marks an important milestone on the journey toward achieving greater success and growth.
